TIO Bioventures is a venture creation firm established in 2019 and located in New York, New York. The firm specializes in funding and advancing innovative biotechnology companies within the healthcare sector. TIO Bioventures aims to support the development of transformative healthcare solutions by providing the necessary financial resources and strategic guidance to emerging companies.
Treadwell Therapeutics Inc. is a clinical-stage oncology company focused on developing innovative therapeutics to meet unmet medical needs in cancer treatment. Founded in 2019 in New York, the company has a robust pipeline that includes several promising candidates, such as CFI-400945, a first-in-class PLK4 kinase inhibitor, and CFI-402257, a best-in-class TTK inhibitor. Additionally, Treadwell is advancing CFI-402411, an oral immunomodulatory kinase inhibitor targeting HPK1. The company also boasts a diverse pre-clinical pipeline featuring multiple biologic and next-generation TCR-based autologous cell therapy programs. With a commitment to exploiting cancer cell vulnerabilities, Treadwell Therapeutics aims to enhance recovery for patients through its innovative drug development efforts.
TCRyption
Seed Round in 2020
TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption seeks to develop a pipeline of product candidates that can treat cancer type and patient populations that are underserved by current approaches.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.